MedTrace Logo

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

NCT03203369 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-07-31

No results posted yet for this study

Summary

A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

BIOLOGICAL

UCART123

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.

Sponsors & Collaborators

  • Cellectis S.A.

    lead INDUSTRY

Principal Investigators

  • Ioana Kloos, MD · Cellectis S.A.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-28
Primary Completion
2019-06-27
Completion
2019-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203369 on ClinicalTrials.gov